{
    "id": 20785,
    "fullName": "CALR L367fs",
    "impact": "frameshift",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "CALR L367fs (reported as L367fs*46) results in a change in the amino acid sequence of the Calr protein beginning at aa 367 of 417, likely resulting in premature truncation of the functional protein (UniProt.org). L367fs*46 results in activation of Jak-Stat signaling, is transforming in culture, and drives myeloproliferative neoplasm formation in animal models (PMID: 26951227).",
            "references": [
                {
                    "id": 5103,
                    "pubMedId": 26951227,
                    "title": "Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26951227"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 811,
        "geneSymbol": "CALR",
        "terms": [
            "CALR",
            "cC1qR",
            "CRT",
            "HEL-S-99n",
            "RO",
            "SSA"
        ]
    },
    "variant": "L367fs",
    "createDate": "04/05/2016",
    "updateDate": "04/06/2018",
    "referenceTranscriptCoordinates": {
        "id": 90939,
        "transcript": "NM_004343",
        "gDna": "chr19:g.(12943757_12943758)",
        "cDna": "c.(1099_1098)",
        "protein": "p.L367fs",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 13582,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Jakafi (ruxolitinib) inhibited growth of transformed cells expressing CALR L367fs in culture (PMID: 26668133).",
            "molecularProfile": {
                "id": 21266,
                "profileName": "CALR L367fs"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11173,
                    "pubMedId": 26668133,
                    "title": "Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26668133"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13577,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, two myelofibrosis patients harboring CALR L367fs (reported as L367fs*46 for patient 1 and L367fs*48 for patient 2) and wild-type JAK2 demonstrated a greater than 50% reduction in spleen size following treatment with Inrebic (fedratinib) (PMID: 24645956).",
            "molecularProfile": {
                "id": 21266,
                "profileName": "CALR L367fs"
            },
            "therapy": {
                "id": 911,
                "therapyName": "Fedratinib",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3954,
                    "pubMedId": 24645956,
                    "title": "JAK inhibitor in CALR-mutant myelofibrosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24645956"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13585,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Jakafi (ruxolitinib) and Torisel (temsirolimus) acted synergistically to inhibit growth of transformed cells expressing CALR L367fs in culture (PMID: 26668133).",
            "molecularProfile": {
                "id": 21266,
                "profileName": "CALR L367fs"
            },
            "therapy": {
                "id": 6845,
                "therapyName": "Ruxolitinib + Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11173,
                    "pubMedId": 26668133,
                    "title": "Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26668133"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13705,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "The presence of the CALR type 1 mutation, L367fs, or a type 1-like mutation is associated with improved overall survival compared to a CALR type 2 (K385fs) or CALR type 2-like mutation and JAK2 V617F in patients with myelofibrosis (NCCN.org).",
            "molecularProfile": {
                "id": 21266,
                "profileName": "CALR L367fs"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 21266,
            "profileName": "CALR L367fs",
            "profileTreatmentApproaches": [
                {
                    "id": 8515,
                    "name": "JAK2 Inhibitor - ATP competitive",
                    "profileName": "CALR L367fs"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 90939,
            "transcript": "NM_004343",
            "gDna": "chr19:g.(12943757_12943758)",
            "cDna": "c.(1099_1098)",
            "protein": "p.L367fs",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}